Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week low Wednesday as it is currently trading at $11.66, below its previous 52-week low of $11.67 with 944,952 shares traded as of 11:35 a.m. ET. Average volume has been 5.3 million shares over the past 30 days.
Warner Chilcott has a market cap of $2.95 billion and is part of the health care sector and drugs industry. Shares are down 2.1% year to date as of the close of trading on Tuesday.
Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. The company has a P/E ratio of 13.3, above the average drugs industry P/E ratio of 10.3 and below the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Warner Chilcott as a
. The company's strengths can be seen in multiple areas, such as its expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow. You can view the full
or get investment ideas from our
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now